Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 Mar;47(3):361–366. doi: 10.1038/bjc.1983.54

Human lymphoblastoid interferon in the treatment of small cell lung cancer.

D H Jones, N M Bleehen, A J Slater, P J George, J R Walker, A K Dixon
PMCID: PMC2011299  PMID: 6299317

Abstract

Ten patients with small cell lung cancer were treated with high dose human lymphoblastoid interferon (50-100 megaunits m-2) for 5 days, followed by low dose interferon (3 megaunits m-2) for 3 weeks. At the end of treatment, and one month later, there was no evidence of either complete or partial response. The treatment produced fever, anorexia and weight loss, with transient leucopenia and thrombocytopenia; there was evidence of a non-cholestatic elevation of serum alanine aminotransferase, with clinical deterioration in the condition of three patients presenting with hyponatraemia. A transient hypocalcaemia during high dose therapy was also noted. It seems that lymphoblastoid interferon as a single agent is unlikely to have a role in the treatment of small cell lung cancer, and that its administration as employed in this study is associated with considerable toxicity.

Full text

PDF
361

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen G., Fantes K. H. A family of structural genes for human lymphoblastoid (leukocyte-type) interferon. Nature. 1980 Oct 2;287(5781):408–411. doi: 10.1038/287408a0. [DOI] [PubMed] [Google Scholar]
  2. Greenberg H. B., Pollard R. B., Lutwick L. I., Gregory P. B., Robinson W. S., Merigan T. C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med. 1976 Sep 2;295(10):517–522. doi: 10.1056/NEJM197609022951001. [DOI] [PubMed] [Google Scholar]
  3. Gutterman J. U., Blumenschein G. R., Alexanian R., Yap H. Y., Buzdar A. U., Cabanillas F., Hortobagyi G. N., Hersh E. M., Rasmussen S. L., Harmon M. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980 Sep;93(3):399–406. doi: 10.7326/0003-4819-93-3-399. [DOI] [PubMed] [Google Scholar]
  4. Jordan G. W., Fried R. P., Merigan T. C. Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating, antiviral activity, and host responses to infection. J Infect Dis. 1974 Jul;130(1):56–62. doi: 10.1093/infdis/130.1.56. [DOI] [PubMed] [Google Scholar]
  5. Kajander A., von Essen R., Isomäki H., Cantell K. Interferon treatment of rheumatoid arthritis. Lancet. 1979 May 5;1(8123):984–985. doi: 10.1016/s0140-6736(79)91771-9. [DOI] [PubMed] [Google Scholar]
  6. Mellstedt H., Ahre A., Björkholm M., Holm G., Johansson B., Strander H. Interferon therapy in myelomatosis. Lancet. 1979 Feb 3;1(8110):245–247. doi: 10.1016/s0140-6736(79)90770-0. [DOI] [PubMed] [Google Scholar]
  7. Merigan T. C., Sikora K., Breeden J. H., Levy R., Rosenberg S. A. Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med. 1978 Dec 28;299(26):1449–1453. doi: 10.1056/NEJM197812282992608. [DOI] [PubMed] [Google Scholar]
  8. Priestman T. J. Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant disease. Lancet. 1980 Jul 19;2(8186):113–118. doi: 10.1016/s0140-6736(80)90004-5. [DOI] [PubMed] [Google Scholar]
  9. Rohatiner A. Z., Balkwill F. R., Griffin D. B., Malpas J. S., Lister T. A. A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmacol. 1982;9(2):97–102. doi: 10.1007/BF00265387. [DOI] [PubMed] [Google Scholar]
  10. Scott G. M., Phillpotts R. J., Wallace J., Gauci C. L., Greiner J., Tyrrell D. A. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet. 1982 Jul 24;2(8291):186–188. doi: 10.1016/s0140-6736(82)91031-5. [DOI] [PubMed] [Google Scholar]
  11. Scott G. M., Phillpotts R. J., Wallace J., Secher D. S., Cantell K., Tyrrell D. A. Purified interferon as protection against rhinovirus infection. Br Med J (Clin Res Ed) 1982 Jun 19;284(6332):1822–1825. doi: 10.1136/bmj.284.6332.1822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Secher D. S., Burke D. C. A monoclonal antibody for large-scale purification of human leukocyte interferon. Nature. 1980 Jun 12;285(5765):446–450. doi: 10.1038/285446a0. [DOI] [PubMed] [Google Scholar]
  13. Strander H. Interferons: anti-neoplastic drugs? Blut. 1977 Sep 18;35(4):277–288. doi: 10.1007/BF00996140. [DOI] [PubMed] [Google Scholar]
  14. Von Hoff D. D., Gutterman J., Portnoy B., Coltman C. A., Jr Activity of human leukocyte interferon in a human tumor cloning system. Cancer Chemother Pharmacol. 1982;8(1):99–103. doi: 10.1007/BF00292879. [DOI] [PubMed] [Google Scholar]
  15. Walker J. R., Nagington J., Scott G. M., Secher D. S. An immunoradiometric assay of serum interferon using a monoclonal antibody. J Gen Virol. 1982 Sep;62(Pt 1):181–185. doi: 10.1099/0022-1317-62-1-181. [DOI] [PubMed] [Google Scholar]
  16. Weiss R. B., Minna J. D., Glatstein E., Martini N., Ihde D. C., Muggia F. M. Treatment of small cell undifferentiated carcinoma of the lung: update of recent results. Cancer Treat Rep. 1980 Apr-May;64(4-5):539–548. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES